Please Wait...

Bioclinica Launches Clinical Adjudication Led by Experienced Medical Specialists and Researchers for Enhanced Safety and Efficacy in Clinical Trials

Transforms adjudication process, enabling sponsors to meet regulatory requirements using centralized and independent expert clinical event review

November 30, 2017

DOYLESTOWN, Pa., – Bioclinica®, the world-leading provider of technology-enabled solutions for clinical research, today announces the launch of Bioclinica Clinical Adjudication, a transformational offering in which medical specialists and researchers, backed by advanced technology, lead independent Clinical Event Committee (CEC) review. The new service enables the independent adjudication of clinical events in conformance with regulatory requirements governing clinical trials within all therapeutic areas, including cardiac studies and for Major Adverse Cardiac Events (MACE) committees.

Adjudication committee members located anywhere around the globe are able to access Bioclinica’s web-based system to securely and efficiently review clinical event dossiers. Built-in access control and tracking provides for security, protection and audit trail transparency while giving adjudicators ready access to the required information on every clinical event type.

“Bioclinica’s robust electronic adjudication environment allows clinical study sponsors to successfully modernize from paper-based adjudication to a web-based system for greater efficiency, data integrity, and reduced timelines while breaking down geographic barriers.”

- David Herron, President Medical Imaging & eHealth Solutions, Bioclinica

As a key component of the service, Bioclinica brings in a vast network of medical professionals who specialize in the specific endpoint areas, augmented by Bioclinica’s advanced clinical adjudication software for thorough and efficient review of clinical events. As an alternative to tapping this vast network of medical experts experienced in adjudication, sponsors may use their own recommended adjudicators.

Objective endpoint evaluation and assessment is critical in meeting regulatory agency endpoint review requirements throughout a clinical trial to ensure compliance with protocol criteria. Bioclinica Clinical Adjudication enables sponsors to electronically manage the complete process around safety endpoints ─ from notification of an endpoint at a clinical trial site on through to central review by therapeutic experts ─ for a more efficient, objective, and streamlined process than traditional methods, while delivering added quality and time-saving benefits.

“In collaborating, our technology and medical and scientific experts have completely re-engineered the clinical adjudication process,” Herron said. “By uniting medical and scientific expertise with technology, sponsors are able to leverage automation to virtually process key Events from numerous sources, documented in alignment with the clinical protocol.”

Benefits of Bioclinica Clinical Adjudication include:

  • Complete and accurate capture of protocol-defined endpoints;
  • Quality supporting documentation for suspected endpoints;
  • A standardized means to confirm the endpoint drawing on the medical and scientific expertise of independent experts;
  • Accurate and timely review of events;
  • Transparency in workflow status;
  • Immediate data accessibility via analytics; and
  • Integration with EDC systems to minimize data entry.

“Whether replacing manual methods or upgrading from earlier electronic adjudication alternatives, Bioclinica customers can expect to see tangible results and lasting value,” Herron comments. “Real-time access to adjudication results and data reports helps slash time and resources while decreasing errors and costs to complete adjudication. We’re pleased to bring this unique and beneficial service to the industry.”

About Bioclinica

Bioclinica is a global life science provider that utilizes science and technology to bring clarity to clinical trials – helping companies to develop new life-improving therapies more efficiently and safely. Successful clinical trials require the ability to see key details and uncover hidden insights, and Bioclinica's experienced scientific, medical, and domain experts bring unmatched insight across the development lifecycle, from the initial protocol to post-approval. The company's offerings include medical imaging and cardiac safety services; clinical adjudication; randomization and trial supply management and optimization; electronic and eSource data capture; site and patient payments and budget forecasting; pharmacovigilance and trial management. The company's thousands of employees serve more than 500 pharmaceutical, biotechnology and device organizations – including all top 20 biopharmaceutical companies and leading CROs – through offices in North America, Europe, and Asia.

Learn more about Bioclinica at www.Bioclinica.com and in the Bioclinica Blog. Follow the latest company news and happenings on LinkedIn and Twitter.

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

As #clinicaltrial designs evolve, trial supply management becomes increasingly complex. Adaptive protocols, direct-… https://t.co/cQa00yp9hi
Bioclinica (7 hours ago)
#Clinicaltrials are not only more expensive and more complex, they also take longer than ever to execute. Since man… https://t.co/ZUEXpxulq6
Bioclinica (5 days ago)
#CTMS is integral to #clinicaltrials, but it can be resource-intensive. That's why we created Bioclinica CTMS Direc… https://t.co/pW9ySieiE2
Bioclinica (1 week ago)
Going to SCOPE? Visit Bioclinica at booth 404! #SCOPE2020 https://t.co/MuzWXHoC2y https://t.co/mpveryx7Xs
Bioclinica (2 weeks ago)
In case you missed it: Bioclinica announces additions to Software Solutions leadership. We welcome Guy Crossley, Ri… https://t.co/8VWOO3IPFD
Bioclinica (5 weeks ago)
Meet Chief Science Officer, Thomas Fuerst, Ph.D., to learn more about our musculoskeletal imaging services.… https://t.co/QFQ1HSV4uV
Bioclinica (5 weeks ago)